Amperos vs Waystar

Waystar is Nasdaq-listed (WAY, IPO June 2024, per its 10-K) and, per Fierce Healthcare, closed its acquisition of Iodine Software around October 1, 2025. A hospital patient financial services team wanting financial clearance, claims, denial recovery and patient payments under one contract would buy it. The vendor says it reaches 60% of the U.S. patient population and 1M+ providers. Its homepage shows HITRUST, SOC 2, PCI and HIPAA badges with no scope given.

Amperos has a narrower job. An orthopedic group like Precision Orthopedics and Sports Medicine, a named customer, hands it denied claims, and the vendor's press release cites over 3,000 clinical locations. Its Series A was announced April 22, 2026, led by Bessemer Venture Partners. The site shows a HIPAA badge and an AICPA SOC badge, with SOC 2 not written out.

For a health system RCM director who wants one contract from clearance through patient payments, Waystar is the buy and Amperos is the add-on for denied claims, since Waystar's homepage lists eligibility, estimates, authorizations, remittance and patient payments.